Comparability in respect of severity of dementia and determination of the nature and degree of disabilities in daily living due to dementia are important in population-based surveys. In physical diseases impairment of a system or organ may be established independently of disability using the ICIDH frame-work but there are problems in measuring cognitive abilities apart from the characteristic behavioural limitations and aberrations that constitute the dementia syndrome. Both DSM-III-R and ICD-10 require as a criterion of dementia that social activities are interfered with, and the degree of dependency is the measure of severity. This suggests that assessment of disability should be the first objective, and the mental or physical causes uncovered next. A suitable informant may be the best judge of the nature of the disability. This procedure would show what services demented persons actually require, clarify the implications of dementia for estimates of active life-expectancy, and increase comparability between studies. Problems associated with this approach and the role of cognitive testing are briefly discussed.

Keywords:
Elderly, Population surveys, Dementia, Disability, Cognitive tests
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.